BPC December 31 update

Eyegate EYEG and Onconova ONTX announce offerings - quiet news flow to end 2019

Price and Volume Movers

The final trading day of 2019 saw next to no news flow, with no clinical data readouts nor trial updates. Only a few very minor announcements were released, no doubt due to the time of the year. Markets are closed tomorrow and will re-open on Thursday January 2.

HLS Therapeutics Inc. announced that Health Canada has approved the use of Vascepa to reduce the risk of cardiovascular events. HLS in-licensed rights to Vascepa for the Canadian market from Amarin Corporation (NASDAQ:AMRN). Shares closed up 2% to $21.49.

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) announced a registered direct offering with institutional investors to purchase 500,000 shares at a purchase price of $10 per share, for aggregate gross proceeds of $5m. Shares closed down 18% to $10.02.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) shares closed 20% lower to $0.38 following yet a further direct offering of 27,662,518 shares at a purchase price of $0.3615 per share, for gross proceeds of $10m. Today’s offering is their fourth in just the last six weeks.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

BioXcel Therapeutics, Inc. (BTAI): $14.61; +40%.

Mereo BioPharma Group plc (MREO): $3.28; +32%.

Oncolytics Biotech Inc. (ONCY): $4.76; +23%.

Spring Bank Pharmaceuticals, Inc. (SBPH): $1.58; +20%.

Trillium Therapeutics Inc. (TRIL): $1.03; +18%.

DECLINERS:

Equillium, Inc. (EQ): $3.38; -19%.

Akero Therapeutics, Inc. (AKRO): $22.20; -19%.

Aridis Pharmaceuticals, Inc. (ARDS): $4.45; -16%.

Cassava Sciences, Inc. (SAVA): $5.20; -15%.

Monopar Therapeutics Inc. (MNPR): $16.60; -11%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

NRBO – Gemphire Therapeutics Inc.
NB-01
Diabetic neuropathic pain (DNP)

Phase 3 Phase 3 trial planned 1H 2020.
$135.3 million